Gerald Baker Financial Group LLC Invests $922,000 in Abbott Laboratories $ABT

Gerald Baker Financial Group LLC acquired a new position in Abbott Laboratories (NYSE:ABT) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 8,148 shares of the healthcare product maker’s stock, valued at approximately $922,000.

Several other hedge funds have also recently added to or reduced their stakes in ABT. J. Stern & Co. LLP grew its stake in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at $2,938,892,000. Assenagon Asset Management S.A. raised its stake in shares of Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock valued at $454,784,000 after purchasing an additional 3,330,368 shares in the last quarter. Ninety One UK Ltd acquired a new stake in Abbott Laboratories in the fourth quarter worth about $336,815,000. Finally, Vanguard Group Inc. grew its position in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 expectations with adjusted EPS of $1.31 versus $1.28 expected, showing better-than-expected profitability. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60, above its prior range, signaling confidence in earnings momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Revenue grew 13% year over year, supported by strong demand in medical devices, diagnostics, and emerging markets, which points to broad-based operating strength. Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Positive Sentiment: Heart-device demand and diagnostics growth, including a surge in sales tied to that segment, improved investor sentiment around Abbott’s longer-term growth profile. Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
• Neutral Sentiment: Abbott’s profit fell sharply from a year ago on a GAAP basis, but the decline was offset by stronger sales and guidance, making this more of a quality-over-headline-results story. Abbott Laboratories Sales Rise on Diagnostics Growth
• Negative Sentiment: Broader market and tech sell-off headlines may have slightly tempered enthusiasm, but they were not the main driver of ABT’s move. Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off

Analysts Set New Price Targets

ABT has been the topic of a number of recent analyst reports. Argus dropped their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Bank of America decreased their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. TD Cowen cut their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Mizuho decreased their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $117.61.

Abbott Laboratories Stock Performance

Shares of ABT opened at $98.81 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s 50 day moving average is $89.56 and its 200-day moving average is $102.18. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock has a market capitalization of $172.11 billion, a P/E ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.